Asciminib
Orphan DrugFDA Approved, EMA Approved
Contents
Description
Asciminib is the first specifically targeting ABL myristoyl pocket (STAMP) inhibitor. It provides a new mechanism of action for treating chronic myeloid leukemia, particularly beneficial for patients who have developed resistance to previous TKI therapies.
Indications & Therapeutic Use
Philadelphia chromosome-positive chronic myeloid leukemia
Linked Diseases:
chronic myeloid leukemia
C92.1D015464
Global Availability (4 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Asciminib — GNH India
15 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Asciminib products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Asciminib
| Generic Name | asciminib |
| Brands | 1 brand available |
| Active Ingredient | asciminib hydrochloride |
| Drug Class | Philadelphia chromosome-positive chronic myeloid leukemia |
| Manufacturer | Novartis |
| Dosage Forms | Oral tablets, 20mg and 40mg |
| Medical Code | L01EA04 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT02081378 |
| Countries | 4 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations5 Validated Nodes